KG-1a Xenograft Model Service for AML

The KG-1a cell line, a prominent and less-differentiated variant of the human acute myeloid leukemia (AML) lineage, offers an invaluable in vivo translational platform for modeling advanced myeloid malignancies and evaluating the therapeutic efficacy of novel target-directed drug candidates. As an industry-leading preclinical contract research organization, Alfa Cytology delivers a fully integrated, turnkey KG-1a Xenograft Model Service designed to support global biopharmaceutical innovators with highly reproducible, robust data packages that accelerate hematological oncology drug discovery.

Overview of KG-1a Xenograft Model for AML

The KG-1a xenograft model serves as a specialized and characteristically unique in vivo model system within hematological malignancy research, providing a direct translational pipeline for investigating AML. Derived as a subclone of the parental KG-1 line, KG-1a cells exhibit a more primitive, undifferentiated myeloblast morphology and completely lack the capacity to respond to certain differentiation-inducing stimuli. By transplanting these human AML-derived promyelocytic blasts into specialized immunodeficient mouse strains, this model successfully recapitulates systemic leukemia progression, bone marrow infiltration kinetics, and peripheral blood pathophysiological environments seen in clinical patient populations.

Biologically, the KG-1a model is highly recognized for its stable and efficient systemic engraftment parameters. Its predictable expansion kinetics provide pre-clinical investigators with a consistent experimental window to assess multi-dose therapeutic interventions and pharmacokinetic/pharmacodynamic (PK/PD) relationships. This model uniquely preserves critical human myeloid stem-like phenotypic features, surface antigen profiles (including high CD34 expression), and aberrant intracellular signaling mechanisms that drive uncontrolled blast proliferation. Consequently, the KG-1a platform is extensively deployed in preclinical screening programs to evaluate the antileukemic potency of novel small-molecule inhibitors, targeted monoclonal antibodies, epigenetic modifiers, and combination systemic chemotherapy regimens.

Fig 1. Overexpression of CX43 promoted mitochondrial transfer from BMSCs to KG-1a cells. (Fu H, et al., 2024)

Cell Line Information: KG-1a

The KG-1a cell line was established as a spontaneous, undifferentiated subclone of the human myeloid cell line KG-1, which originally originated from the bone marrow of a patient diagnosed with erythroleukemia that progressed into AML. When cultured as uniform suspension cultures under standard in vitro conditions, these cells maintain a stable primitive myeloblast phenotype and serve as a cornerstone model for stem-like AML biology research.

Our Services

Workflow of KG-1a Xenograft Model Construction

• Cell Culture & Quality Control: Human KG-1a cells are expanded in vitro using certified growth media under strictly optimized environmental parameters. STR profiling and mycoplasma clearance verification are completed prior to harvesting to guarantee absolute biological purity and phenotypic identity.
• Host Selection & Acclimatization: Healthy, standardized immunocompromised mice are sourced from validated vendors. The animals undergo a dedicated acclimatization phase within a controlled facility to establish stable baseline physiological metrics.
• Precision Inoculation: A calibrated suspension of high-viability KG-1a cells is prepared in a sterile physiological buffer. The cell mixture is precisely inoculated in vivo into designated rodent cohorts via tail vein intravenous routes to facilitate systemic leukemic distribution.
• Longitudinal Growth Tracking: Following successful inoculation, leukemic progression is systematically monitored using FACS to detect human CD45+ or specific myeloid markers in peripheral blood samples. Animal body weights, physical baselines, and general behavioral health are routinely documented.
• Stratification & Dosing: When systemic leukemic burden reaches a predetermined, statistically optimal range, the mice are randomized into matched experimental cohorts. This stratification step ensures balanced baseline dimensions across all groups before customized therapeutic dosing regimens commence.

Fig 2. KG-1a Xenograft Model Construction Workflow

Case Study - KG-1a Xenograft Model Development

A pre-clinical validation study was conducted utilizing the KG-1a xenograft model to evaluate the anti-tumor efficacy of a novel targeted small-molecule inhibitor designed for AML. Following precision intravenous inoculation of human KG-1a cells into immunodeficient mice, the animals demonstrated steady, systemic leukemic engraftment and a highly predictable disease progression across all study cohorts. Animals assigned to the active treatment group exhibited a clear, statistically significant reduction in circulating leukemic blasts and prolonged survival times compared to the vehicle control group, confirming the model's high sensitivity and robust predictive reliability for screening targeted AML therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Specialized knowledge in the cultivation and maintenance of diverse squamous cell carcinoma lineages, providing reliable in vivo platforms for complex AML studies.
• Rigorous Quality Control: Stringent validation at every phase of in vitro and in vivo processing to completely eliminate confounding biological variables.
• Tailored Experimental Design: Flexible study frameworks accommodating custom mouse strain choices, specific dosing routes, and orthotopic or subcutaneous inoculation pathways.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready data report providing comprehensive digital caliper metrics and robust statistical validations.

Contact us

Accelerating your AML pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing utilizing our KG-1a platform, please reach out to us today to discuss your project layout with our scientific team.

For research use only. Not intended for any clinical use.